Positives

• Patients in animal proof-of-concept models showed AER-271 ameliorated cerebral edema, attenuated neurologic deficits, and prevented neuronal death, providing rationale for testing in COVID-related neuroinflammation PMC.
  
  
• Healthy volunteers in the Phase 1 trial of the IV prodrug tolerated AER-271 well, supporting safety for further development in CNS edema and water-channel-related conditions Aeromics.
  
  

Negatives

• A Long COVID patient seeking AER-271 will find the molecule's clinical program focused on acute ischemic stroke and brain edema rather than PASC, with no published Long COVID readouts available Aeromics.
  
  
• Animal data also showed AER-271 suppresses glymphatic fluid transport, raising concern that long-term aquaporin-4 inhibition could impair brain waste clearance in chronic patients PubMed.
  
  

Hurdles & Side Effects

• Patients cannot access AER-271 outside of an active stroke trial, as Aeromics' expanded access program is highly restrictive Aeromics.
  
  
• A patient interested in the IV prodrug must also accept that delivery requires hospital infusion, ruling out at-home or chronic outpatient use Aeromics.